May 27, 2017
Recommended Topic Related To:


"The US Food and Drug Administration (FDA) has approved pembrolizumab (Keytruda, Merck) for children and adults who have classical Hodgkin lymphoma (cHL) that has resisted treatment or relapsed after three or more prior lines of therapy."...



Elitek Patient Information including How Should I Take

What should I discuss with my healthcare provider before receiving rasburicase (Elitek)?

You should not receive this medication if you have ever had an allergic reaction or blood cell problems after receiving rasburicase, or if you have an enzyme deficiency called glucose-6-phosphate dehydrogenase deficiency (G6PD).

If you are of African or Mediterranean descent, you may need a rasburicase dose adjustment or special tests:

FDA pregnancy category C. It is not known whether rasburicase will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication..

It is not known whether rasburicase passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How is rasburicase given (Elitek)?

Rasburicase is injected into a vein through an IV. You will receive this injection in a clinic or hospital setting. Rasburicase must be given slowly, and the IV infusion can take at least 30 minutes to complete.

Rasburicase is usually given once per day for up to 5 days. Follow your doctor's dosing instructions very carefully.

To be sure this medicine is helping your condition and is not causing harmful effects, your blood will need to be tested often. Visit your doctor regularly.

Side Effects Centers

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Get the latest treatment options.